Novartis and Vernalis in cancer deal; alliance ends
The Novartis Institutes for Biomedical Research has licensed exclusive worldwide rights to Vernalis PLC's (oncology and neurology) Hsp90 cancer research program. The deal follows a six-month evaluation period entered into by the companies last year in which Novartis had the option to license rights to the project.
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.